Reticulocyte hemoglobin content and iron therapy in chronic kidney disease: Reply of the Anemia group of the Spanish Society of Nephrology Aleix Cases, Patricia de Sequera, Borja Quiroga, Maria Jesús Puchades, Leyre Martin-Rodriguez, José Luis Gorriz, José Portolés

Should we modify hemoglobin targets in CKD patients? FDA and EMEA statements A. L. Martín De Francisco, P. Aljama, M. Arias, J. L. Górriz, A. Martínez Castelao, J. Portolés

Heart failure in patients with kidney disease and iron deficiency: The role of iron therapy Aleix Cases Amenós, Raquel Ojeda López, José María Portolés Pérez